TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer

NCT05550025 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: camrelizumab& apatinib

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Collaborators

[object Object]